Tolerance and cross-tolerance to cannabinoids in mice: Schedule-controlled responding and hypothermia

Psychopharmacology

Volumn 215, Issue 4, 2011, Pages 665-675

  Singh, Harinder ^a   Schulze, David R ^a   McMahon, Lance R ^a  

^a University of Texas Health Science Center   (United States)

Author keywords

Agonist efficacy; Cannabinoid; CB1; Crosstolerance; Delta 9 tetrahydrocannabinol; Hypothermia; Mouse; Schedule controlled behavior; Tolerance

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; DRONABINOL; MIDAZOLAM; RIMONABANT; CANNABINOID; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CROSS TOLERANCE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SENSITIVITY; FOOD INTAKE; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; INSTRUMENTAL CONDITIONING; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECTUM TEMPERATURE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; DRUG POTENTIATION; DRUG TOLERANCE; PATHOPHYSIOLOGY; TIME;

ANIMALS; BEHAVIOR, ANIMAL; CANNABINOIDS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; HYPOTHERMIA; MALE; MICE; MICE, INBRED C57BL; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; TIME FACTORS;

EID: 80052935801     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-2162-7     Document Type: Article

References (45)

1. Abood ME, Martin BR (1992) Neurobiology of marijuana abuse. Trends Pharmacol Sci 13:201-206
2. Adams IB, Compton DR, Martin BR (1998) Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209-1217
3. Breivogel CS, Childers SR (2000) Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J Pharmacol Exp Ther 295:328-336
4. 9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73:2447-2459
5. 9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur J Pharmacol 459:139-150
6. Childers SR (2006) Activation of G-proteins in brain by endogenous and exogenous cannabinoids. AAPS J 8:E112-E117
7. 1 receptors in hippocampal neurons. J Neurosci 21:2425-2433
8. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371-9376
9. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949
10. De Vry J, Jentzsch KR (2004) Partial agonist-like profile of the cannabinoid receptor antagonist SR141716A in a food-reinforced operant paradigm. Behav Pharmacol 15:13-20
11. De Vry J, Jentzsch KR, Kuhl E, Eckel G (2004) Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15:1-12
12. Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38:151-178
13. Dill JA, Howlett AC (1988) Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J Pharmacol Exp Ther 244:1157-1163
14. Di Marzo V, Berrendero F, Bisogno T, González S, Cavaliere P, Romero J, Cebeira M, Ramos JA, Fernández-Ruiz JJ (2000) Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J Neurochem 74:1627-1635
15. 9-tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology 35:1775-1787
16. Fan F, Compton DR,Ward S,Melvin L,Martin BR (1994) Development of cross-tolerance between Δ 9-tetrahydrocannabinol, CP 55, 940 and WIN 55, 212. J Pharmacol Exp Ther 271:1383-1390
17. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkow ND (1999) Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 288:478-483
18. Giuffrida A, McMahon LR (2010) In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins Other Lipid Mediat 91:90-103
19. Giuffrida A, Piomelli D (1998a) Purification and high-resolution analysis of anandamide and other fatty acylethanolamides. In: Laychock SG, Rubin RP (eds) Lipid second messengers. CRC, Boca Raton, pp 113-133
20. Giuffrida A, Piomelli D (1998b) Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett 422:373-376
21. Hardison S, Weintraub ST, Giuffrida A (2006) Quantification of endocannabinoids in rat biological samples by GC/MS: technical and theoretical considerations. Prostaglandins Other Lipid Mediat 81:106-112
22. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583
23. Hollister LE (1986) Health aspects of cannabis. Pharmacol Rev 38:1-20
24. Howlett AC (2002) The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68-69:619-631
25. 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology 156:369-380
26. 9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A. Eur J Pharmacol 466:121-127
27. Kenakin T (1997) Pharmacologic analysis of drug-receptor interaction. Lippincott-Raven, Philadelphia
28. Kenakin T (2002) Efficacy at G-protein-coupled receptors. Nat Rev Drug Discov 1:103-110
29. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R, Ward SJ (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40:471-478
30. 9-tetrahydrocannabinol. Psychopharmacology 203:219-228
31. Mechoulam R, Gaoni Y (1965) A total synthesis of DL-delta-1- tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 87:3273-3275
32. National Research Council (2003) Guidelines for the care and use of mammals in neuroscience and behavioral research. National Academies, Washington
33. Oviedo A, Glowa J, Herkenham M (1993) Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 616:293-302
34. Pertwee RG (1988) The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 36:189-261
35. Pertwee RG, Stevenson LA, Griffin G (1993) Cross-tolerance between Δ 9-tetrahydrocannabinol and the cannabimimetic agents, CP 55, 940, WIN 55, 212-2 and anandamide. Br J Pharmacol 110:1483-1490
36. 9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 47:33-40
37. 9-tetrahydrocannabinol desensitizes CB1-, adenosine A1-, and GABAB-mediated inhibition of adenylyl cyclase in mouse cerebellum. Mol Pharmacol 66:1275-1284
38. 35S]GTPgammaS autoradiography in rat brain. J Neurosci 16:8057-8066
39. 1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol 160:454-466
40. 9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 321:370-380
41. Tallarida RJ (2000) Drug synergism and dose-effect data analysis. Chapman and Hall, Boca Raton
42. Wiley J, Balster R, Martin B (1995) Discriminative stimulus effects of anandamide in rats. Eur J Pharmacol 276:49-54
43. Wiley JL, Golden KM, Ryan WJ, Balster RL, Razdan RK, Martin BR (1997) Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys. Pharmacol Biochem Behav 58:1139-1143
44. Wiley JL, Razdan RK, Martin BR (2006) Evaluation of the role of the arachidonic acid cascade in anandamide's in vivo effects in mice. Life Sci 80:24-35
45. Willoughby KA, Moore SF, Martin BR, Ellis EF (1997) The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282:243-247